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Abstract
Background: To mitigate the cardiotoxicity of anthracycline antibiotics without compromising their anticancer activities is
still an issue to be solved. We previously demonstrated that schisandrin B (Sch B) could protect against doxorubicin (Dox)-
induced acute cardiotoxicity via enhancing cardiomyocytic glutathione redox cycling that could attenuate oxidative stress
generated from Dox. In this study, we attempted to prove if Sch B could also protect against Dox-induced chronic
cardiotoxicity, a more clinically relevant issue, without compromising its anticancer activity.
Methodology: Rat was given intragastrically either vehicle or Sch B (50 mg/kg) two hours prior to i.p. Dox (2.5 mg/kg)
weekly over a 5-week period with a cumulative dose of Dox 12.5 mg/kg. At the 6th and 12th week after last dosing, rats
were subjected to cardiac function measurement, and left ventricles were processed for histological and ultrastructural
examination. Dox anticancer activity enhanced by Sch B was evaluated by growth inhibition of 4T1, a breast cancer cell line,
and S180, a sarcoma cell line, in vitro and in vivo.
Principal Findings: Pretreatment with Sch B significantly attenuated Dox-induced loss of cardiac function and damage of
cardiomyocytic structure. Sch B substantially enhanced Dox cytotoxicities toward S180 in vitro and in vivo in mice, and
increased Dox cytotoxcity against 4T1 in vitro. Although we did not observe this enhancement against the implanted 4T1
primary tumor, the spontaneous metastasis to lung was significantly reduced in combined treatment group than Dox alone
group.
Conclusion: Sch B is capable of protecting Dox-induced chronic cardiotoxicity and enhancing its anticancer activity. To the
best of our knowledge, Sch B is the only molecule ever proved to function as a cardioprotective agent as well as a
chemotherapeutic sensitizer, which is potentially applicable for cancer treatment.
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Introduction
Anthracycline antibiotics (doxorubicin, epirubicin, daunorubi-
cin, idarubicin, etc.) are a class of anticancer agents whose roles in
cancer chemotherapy are indispensable. Nevertheless, anthracy-
cline treatment can be accompanied with an irreversible
cardiotoxicity [1,2,3,4] . Although it is still difficult to separate
the primary mechanisms from the subsequent molecular events
that lead to cardiotoxicity, many lines of evidence support that
anthracycline antibiotics damage cardiomyocytes through gener-
ation of superoxide anion and further converting it to even more
reactive hydroxyl free radical [1]. Anthracyclines can also disturb
cellular antioxidative systems such as inactivating GSH peroxidase
and exacerbating oxidative stress [5,6]. Quenching ROS (super-
oxide anion, hydroxyl peroxide, and hydroxyl free radical)
generated from Dox in cardiomyocytes is thus one of the major
pharmacological approaches to prevent anthracycline-induced
cardiotoxicity [1,2,3,7,8].
Sch B (Fig. 1), the most abundant dibenzocyclooctadiene lignan
present in Schisandra chinensis (Turcz.) Baill, can protect against
oxidative stress including carbon tetrachloride-induced hapato-
toxicity [9], myocardical ischemia/reperfusion injury [10,11], and
brain oxidative damage [12], through upregulation of GSH redox
cycling. We recently demonstrated that Sch B was able to prevent
Dox-induced acute cardiotoxicity, via enhancing cardiomyocytic
glutathione redox cycling that could remove excessive ROS
generated from Dox [13,14]. Nevertheless, we do not know if this
compound is also effective in preventing Dox-induced chronic
toxicity. On the basis of previous reports, compounds that are
effective in preventing acute cardiotoxicity (which appear within
hours or days) induced by a singly high dose of Dox are not
necessarily effective in preventing chronic toxicity (which takes
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can prevent anthracycline-induced chronic cardiotoxicity.
Another equally important issue is if Sch B could decrease Dox
anticancer activity. We have demonstrated that Sch B was a dual
inhibitor of P-glycoprotein and multidrug-resistance associated
protein, and thus could sensitize drug-resistant cells to many
structurally and functionally unrelated drugs including anthracy-
cline antibiotics as the substrates of the 2 drug pumps
[13,16,17,18]. We also demonstrated that Sch B enhanced Dox
anticancer activities in vivo against KBv200 (a human epidermoid
carcinoma cell line overexpressing P-glycoprotein inoculated s.c.
in nude mice) [19]. Fong et al. added the mechanism whereby the
compounds in this chemical class inhibited P-glycoprotein [20].
Sch B was also able to enhance doxorubicin (vincristine, or
mitoxantrone)-induced apoptosis in HMMC7721, a human
hepatic cancer cell line, and MCF-7, a human breast cancer cell
line, through activation of mitochondrial apoptotic pathway,
without obvious enhanced toxicities toward normal cells, such as
primary rat cardiomyocytes and primary human fibroblasts [16].
While the above studies were mostly performed in vitro, there is a
need to determine if Sch B would interfere with Dox anticancer
activities in vivo.
In this communication, we demonstrate that Sch B is able to
protect against Dox-induced chronic cardiotoxicity, and enhances
Dox anticancer activities against S180 sarcoma and 4T1 breast
cancer in vivo.
Results
Sch B alleviates general toxicity of Dox
When compared with rats in control and Sch B groups that
maintain similar growth rates, rats receiving Dox alone showed a
much slower gain of the body weight starting from the 3rd week of
treatment. Such Dox-related weight loss was partially alleviated in
rats receiving SchB and Dox combined, which gained more weight
than those receiving Dox alone, the difference was significant at
the 4th week, P,0.05 (Figure S1A). Similar results were obtained
in mice (Figure S1B). Moreover, 100 mg/kg of Sch B appeared to
be more protective against weight loss than 50 mg/kg of Sch B,
suggesting that its protective effect is dose-dependent. Regarding
the mortality, one rat receiving Dox (n=24) died of ascites six
weeks after last dose of Dox, another 3 (n=12) died of wasting or
ascites, whereas only 1 receiving Sch B and Dox (n=12) died of
ascites between the 6th and 12th week after last dose of Dox.
Taken together, these data demonstrate that Sch B alleviates
general toxicity of Dox.
Sch B prevents chronic myocardial damage
To evaluate the myocardial damage induced by chronic Dox
treatment, histological and ultrastructural changes of cardiomyo-
cytes were examined. An overall view of the distribution of
myocardial damage at the light microscopy level was shown in
Figure 2A to 2H. No obvious abnormalities were observed in
control (Figure 2A and 2E) and Sch B group (Figure 2B and 2F),
while severe myocardial damages were found in Dox group,
characterized by disorganization of myofibrillar arrays, cytoplas-
mic vacuolization (Figure 2C and 2G). Pretreatment with Sch B
prevented marked cardiomyocytic vacuolization induced by Dox
(Figure 2D and 2H). Similar pattern of damages was observed at
the ultrastructural level (Figure 2I–2P). The control (Figure 2I and
2M) and Sch B groups (Figure 2J and 2N) did not show significant
morphological abnormalities. However, Dox treatment led to loss
of myofibril, vacuolization of cytoplasm (Figure 2K) and swelling
of mitochondria with membrane disruption (Figure 2O), which
was markedly attenuated by pretreatment of Sch B (Figure 2L and
2P).
Sch B attenuates Dox-induced chronic cardiac
dysfunction
As shown in Figure 3, at the 6th week after last dosing of Dox,
rats receiving Sch B alone did not show any obvious abnormal
cardiac function compared with vehicle controls. Dox alone led to
significant cardiac dysfunction characterized by decrease in LVSP,
left ventricular developed pressure (LVDP), +dP/dtmax and 2dP/
dtmax, as well as increased LVEDP. Pretreatment of Sch B
prevented the Dox-induced loss of cardiac function. Similar results
were obtained at the 12th week after last dosing of Dox (Figure
S2). Taken together, these data indicated that Dox-induced
chronic loss of cardiac function was significantly attenuated by
pretreatment of Sch B.
Sch B enhances Dox activities against tumor growth in
vitro and in vivo
As shown in Figure 4, Sch B significantly increased Dox-
induced growth inhibition of S180 in vitro (Figure 4A) and in vivo
(Figure 4C). With 4T1 model, Sch B significantly enhanced Dox
cytotoxicity toward 4T1 in vitro (Figure 4B). Although there was
no significant difference of the implanted 4T1 tumor size and
tumor weight between Dox+Sch B group and Dox alone group
(Figure 4D and 4E), the combined treatment (Dox+Sch B)
significantly reduced the spontaneous metastatic foci formed in
lung (Figure 4F). We did not find metastasis in other organs, which
was consistent with the general metastatic feature of this cell line,
i.e., subcutaneous inoculation of 4T1 led to mainly pulmonary
metastasis [21].
Discussion
This communication, combined with our previous reports
[13,16,17,18,22,23], provides evidence that Sch B can protect
Dox-induced acute and chronic cardiotoxicity and enhancing its
anticancer activity.
In this study, slower weight gain was found in rats receiving Dox
alone, while addition of Sch B could partially prevent weight loss
caused by Dox. Decreased food intake due to gastrointestinal side
effect and worsened general condition may contribute to slower
growth of rats. Moreover, Dox has been shown to inhibit mTOR
signaling and reduces cardiac mass [24]. mTOR plays a central
Figure 1. The chemical structure of schisandrin B.
doi:10.1371/journal.pone.0028335.g001
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growth, proliferation and energy metabolism. It is likely that Sch B
partially relieve the Dox-induced mTOR inhibition in muscle or
adipose tissue, thereby affecting body weight in rats. Development
of ascites is at least in part due to chronic heart failure, there were
less rats died of ascites in Sch B+Dox than Dox-only group (1
versus 3),which is consistent with cardioprotective function of Sch
B.
It is difficult to remove ROS generated from Dox. First, the
generation of ROS through quinone redox cycling is highly
efficient, because it is an reaction catalyzed by a number of
NAD(P)H-oxidoreductases [1]. Second, the molecular event is
amplified due to its cycling nature, i.e., a molecule of Dox would
continuously produce ROS as long as the cycle is not disrupted.
Third, Dox, with a long in vivo elimination half-life, exerts chronic
and chaotropic effects on cardiomyocytes [25,26]. The reason
some antioxidants like vitamin E and N-acetylcysteine are not
effective in preventing chronic cardiotoxicity [15] is probably due
to their pharmacokinetic features, e.g., their effectiveness is
critically dependent on the cardiac distribution and elimination
that should match Dox.
In order to effectively remove ROS generated from Dox, it is
essential to activate antioxidative systems which are a match to
quinone redox cycling. Glutathione is the most abundant cellular
antioxidant and glutathione redox cycling is the most effective
cellular system against oxidative stress [27]. This redox cycle, in
principle, has the capacity to cope with ROS generated from Dox.
First, GSH redox cycling is enzymatically catalyzed and thus is
highly efficient. Second, a molecule of GSH can quench many
molecules of ROS due to its cycling nature. Third, as long as
NADPH generation pathways via malic enzyme, cytosolic
isocitrate dehydrogenase, and pentose phosphate pathway are
not severely disturbed, GSH redox cycling will function properly
and reduced GSH will remain a stable cellular pool at millimolar
level, which is sufficient for reaction with ROS at nanomolar to
micromolar range. While SOD converts superoxide anion (O
2)t o
hydroperoxide, GSH redox cycling not only scavenges hydroxyl
free radical, but also prevents excessive formation of hydroxyl free
radical by converting superoxide anion and hydroperoxide to
water and oxygen (Figure 5). We previously demonstrated that a
single dosing of Sch B (50–100 mg/kg) was able to upregulate
cardiac GSH redox cycling and superoxide dismutase (SOD) in rat
and mice, and the increased activities of GSH redox cycling and
SOD were lasted for at least 72 hours [13], which was particularly
important for detoxification of continuous production of ROS
from Dox, considering the long cardiac clearance of Dox, which
was closely associated with chronic cardiac toxicity [25,26].
The mechanism underlying Sch B-enhanced redox cycling
remains poorly understood. Recently, Sch B was found to
stimulate cytochrome 450-catalyzed NADPH oxidation reaction
Figure 2. Sch B alleviates Dox-induced myocardial damage in left ventricles of rats. Rats were treated with Dox (2.5 mg/kg, i.p.) with or
without pretreatment of Sch B, weekly over 5 weeks, followed by analysis of light or electron microscope 6 weeks after the last dose of Dox.
Representative images of histology with hematoxylin-eosin staining (A–H) and ultrastructure (I–P) are shown.
doi:10.1371/journal.pone.0028335.g002
Sch B Prevents Dox-Induced Cardiotoxicity
PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e28335resulting in low level of ROS production, which in turn triggers
redox signaling through ERK/Nrf2 pathway so as to promote cell
survival [28,29]. Yoshida et al. suggested that pitavastatin
attenuates chronic doxorubicin cardiotoxicity through its antiox-
idant effect involving Rac1 inhibition [30]. Since Rac1 is a
requisite component of NADPH oxidase, its role in Sch B-induced
antioxidant activity remains to be studied.
In this study, we demonstrated that Sch B enhanced growth
inhibition of S180 and 4T1 by Dox in vitro, consistent with our
previous data [16]. We have shown that enhancement 0.6 or
1.2 nmol/kg (0.3–0.6 mg/kg)of Dox-induced apoptosis by Sch B
in cancer cells was associated with the activation of caspase-9
rather than caspase-8 [16]. However, the signaling pathway
upstream the caspase activation is not clear. Nishida et al.
demonstrated that Sch B serves as a specific ATR protein kinase
inhibitor and abolishes the G2/M and S-phase checkpoints in
DNA damage response [31], interfering with effective DNA
repair. Thus, disruption in ATR checkpoint pathway following
Sch B treatment will sensitize cells to Dox-induced apoptosis. It
seemed that Sch B had different effect on Dox in different tumors,
i.e., Sch B enhanced Dox activity toward implanted S180 but not
4T1. This not surprising, because in vivo anticancer activity of a
drug was to the great extent determined by the complex
pharmacokinetic feature and the anticancer activities of a drug
were often obvious in some animal models but not in others
[32,33]. The blood vessels in S180 tumors were drastically more
pronounced and much more homogeneously distributed through-
out the sections than those in 4T1 tumors (Figure S3). This could
substantially limit the drug penetration and ultimately significantly
reduce Dox and Sch B concentration in 4T1 tumor. Considering
the dose-dependent characteristics (the least effective concentra-
tions of both Dox and Sch B) [17,18,22,23], the enhancing effect
by Sch B could be abolished. Nevertheless, Sch B combined with
Dox significantly reduced spontaneous metastatic foci in lung.
This antimetastatic effect was conceivably resulted from killing
metastatic cells at solitary cell stage (starting from metastatic cells
separated from mother body to before forming a mass), similar to
Sch B effect on Dox in vitro system where cancer cells were
‘solitary’ rather than tissue-like mass (tumor). Up to date, all the in
vitro and in vivo studies without exception demonstrated that Sch
B enhanced Dox anticancer activities [13,16,17,18,19,20,22,
34,35], and there has been no single experiment in vitro and in
vivo that ever demonstrated the adverse effect of Sch B on Dox
anticancer activities (or any other tested anticancer agents,
including anthracyclines, vinca alkaloids, taxanes, epipodophyllo-
toxins, antimetabolites, DNA topoisomerase inhibitors, tyrosine
kinase inhibitors, among others) for the last 7 years of our
continuous studies on this compound.
The mechanisms that Sch B has different effects on the
susceptibility of cancer cells and cardiomyocytes toward Dox, as
Dox basically induces apoptosis in both [1] have been discussed in
great detail in our previous report [13,16] and would not be
discussed here.
To the best of our knowledge, Sch B is probably the only
molecule so far reported to function as a cardioprotective agent
against Dox as well as a chemotherapeutic sensitizer. This
molecule has potential clinical application [13,19].
Materials and Methods
Reagents
Dox was from Sigma, and Sch B (purity, 99.12% by HPLC) was
from the Winherb Medical Science Co., Ltd, Shanghai, China.
Cell lines
S180 and 4T1 cells were cultured in RMPI 1640 medium
containing 10% fetal bovine serum in a humidified CO2 incubator
at 37uC. Cell lines were obtained from and characterized by The
Cell Bank of Type Culture Collection of Chinese Academy of
Sciences according to the cell line authentication testing (vitality,
Figure 3. Sch B attenuates chronic cardiac functional loss caused by Dox. Rats were treated with Dox (2.5 mg/kg, i.p.) with or without
pretreatment of Sch B (50 mg/kg intragastrically), weekly for 5 weeks. Cardiac function was measured in 6 weeks. **, P,0.05.
doi:10.1371/journal.pone.0028335.g003
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fingerprinting and mycoplasma contamination) and were used
within 6 months after resuscitation.
Animals
Male Sprague-Dawley rats, Balb/c mice were purchased from
Shanghai SLAC Laboratory Animal Co., Ltd, Shanghai, China.
Figure 4. Sch B enhances the anticancer activity of the Dox in vitro and in vivo. A and B, in vitro growth inhibition rates of S180 cells (A)
and 4T1 (B) by Dox in the presence or absence of Sch B. The inhibition rate was calculated as the ratio of the treated over the control. *, P,0.05. C–F,
in vivo growth inhibition of S180 and 4T1 by Dox with or without Sch B. C, S180 tumor volume, **, P,0.05, Sch B+Dox versus Dox group; D, E, & F,
4T1 tumor volume, tumor weight, and pulmonary metastatic foci in 4T1 mice model (data were collected 28 days after 4T1 cell inoculation). The data
were collected **, P,0.05, Dox, Sch B+Dox versus control group; E, 4T1 tumor weight, **, P,0.05, Dox, Sch B+Dox versus control group; F, , **, P
,0.05, Sch B+Dox versus Dox group.
doi:10.1371/journal.pone.0028335.g004
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(2362uC), humidity (5065%), and a 12 h light/dark cycle. The
animals had free access to sterile food and water.
Ethics
The study was approved by the institutional animal ethical
committee of the hospital with approval IDzju2008-1-02-015.
Cell proliferation assay
A nonradioactive cell proliferation assay (CellTiter96, Promega)
was used to perform an MTT assay. S180 or 4T1 cells were seeded
at a density of 5610
3 cells/well in 96-well plates and incubated
with Dox of indicated concentration in the presence or absence of
50 mM Sch B as described by us previously [16,17,18,22,23]. At
72 hours after plating, MTT assays were performed according to
the manufacturer’s instructions. Data were collected by reading at
570 nm with a model ELX800 Micro Plate Reader (Bio-Tek
Instruments Inc., Highland Park, USA). The percentage of growth
inhibition was calculated by the following formula: percentage of
cell inhibition=(mean absorbance in test wells)/(mean absorbance
in control wells)6100.
Chronic cardiotoxicity rat model
The protocol is modified based on the schedule described by
Sacco G et al [36]. In brief, rats were randomly assigned into four
groups (n=24, per group): (a) control, (b) Sch B, (c) Dox, and (d)
Sch B+Dox. Each rat, depending on the treatment group, was
given intragastrically either vehicle (0.5% paraxamer) or Sch B
(50 mg/kg) two hours prior to i.p. either saline or Dox (2.5 mg/kg)
weekly over a 5-week period. Thus, cumulative dose of Dox were
12.5 mg/kg. Body weight was recorded weekly until the 6th week.
At 6 and 12 weeks after last dose of Dox, 12 rats in each group
were subject to hemodynamic measurement, respectively. At 6
weeks after last dose of Dox, left ventricles from 18 randomly
selected rats (n=4 for control and Sch B, n=5 for Dox and
Dox+Sch B, respectively) were removed, and each ventricle was
split into two: one was fixed in 10% formaldehyde, and paraffin
sections were stained with hematoxylin-eosin for histological
examination; the other was processed for ultrastructural morpho-
logic examination by electron microscopy, as described previously
[37].
Measurement of cardiac function
The studies were performed at the 6th and 12th week after last
dosing of Dox. Left ventricular performance was analyzed in rat
anesthetized with i.p. injections of chloral hydrate (360 mg/kg). A
micro manometer-tipped catheter was inserted into the right
carotid artery and advanced into the left ventricular under
pressure control as described [38]. The left ventricular systolic
pressure (LVSP), left ventricular end diastolic pressure (LVEDP),
maximal rate of rise/fall left ventricle pressure development (+dP/
dtmax, 2dP/dtmax) were recorded. All pressure data were recorded
on MedLab data acquisition system (Nanjing MedEase Co.,
Nanjing, China). The parameters described above were measured
and recorded for at least 30 min.
In vivo tumor models
Balb/c mice were inoculated subcutaneously with 2610
6 4T1
cells/0.2 ml PBS or S180 cells/0.2 ml PBS. Within 24 hours, the
mice were randomly assigned to four groups: (a) control, (b) Sch B,
(c) Dox, and (d) Sch B+Dox. Each mouse received either vehicle or
Sch B (100 mg/kg) intragastrically followed by saline or Dox
(2.5 mg/kg) intraperitoneally every other day for a total of 7 doses.
The size of tumor was recorded twice weekly. Mice were sacrificed
when tumor sizes in control group were .2c m
3 (i.e. 28 days after
cell inoculation), and the tumor and lungs were surgically removed
for measurement.
Statistical analysis
Data are expressed as mean 6 S.E., Statistical comparisons
between different groups were done by using one-way ANOVA
followed by Tukey-Kramer multiple comparisons test (SPSS 10.0).
Significance was accepted at p,0.05.
Supporting Information
Figure S1 Effect of Sch B on the body weights of rats or mice
receiving chronic Dox treatment. A, rats were assigned and treated
as described in Methods. *, P,0.05, versus control or Sch B. B,
Mice were inoculated with S180 cells and then assigned randomly
into 5 groups: control group was given vehicle followed by saline,
SchB group received Sch B and saline, Dox group received Dox
only, SchB1+Dox group received 50 mg/kg Sch B followed by
2 mg/kg Dox, SchB2+Dox received Sch B 100 mg/kg followed
Figure 5. A proposed model for the protective role of Sch B in Dox-induced oxidative stress leading to cardiotoxicity. SOD,
superoxide dismutase; GPX, glutathione peroxidase; GR, glutathione reductase ;
NO2
—, superoxide anion;
NOH, hydroxyl radical; H2O2, hydrogen
peroxide; ﬂ,GSH directly scavenges hydroxyl radial through the reaction: GSH+R
NRGS
N+RH, then GS
N dimerizes to form GSSG.
doi:10.1371/journal.pone.0028335.g005
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versus Sch B2+Dox.
(JPG)
Figure S2 Sch B attenuates chronic cardiac functional loss
caused by Dox. Rats were treated with a Dox (2.5 mg/kg, i.p.)
with or without pretreatment of Sch B (50 mg/kg intragastrically),
weekly for 5 weeks. Cardiac function was measured in 12 weeks.
A, LVSP, maximal left ventricle systolic pressure. B, LVEDP,
maximal left ventricle end-diastolic pressure. C, LVDP, left
ventricle developed pressure. +dP/dt, maximal slope of systolic
pressure increment. E, 2dP/dt, maximal slope of diastolic
pressure decrement. **, P,0.05.
(JPG)
Figure S3 The microvasculature in S180 (A, B) xenograft tumor
was drastically more than that in 4T1 tumor (C, D). The
intratumoral microvasculature was detected by immunohisto-
chemistry performed on paraffin embedded sections. Briefly, after
deparaffination, sections were incubated in 0.3% H2O2 in TBS,
and then blocked with 10% normal goat serum. The primary
antibody anti-CD34 was applied for 1 h, rinsed in TBS, and
followed by incubation with peroxidase labeled goat-anti-rat IgG
antibody for 30 minutes. Sections were visualized by 3-amino-9-
ethylcarbazole (AEC), counterstained with hematoxylin and
mounted. Original magnifications: 6100.
(JPG)
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